New cell therapy trial targets Tough-to-Treat blood cancer
NCT ID NCT07263906
Summary
This early-stage study is testing the safety and finding the right dose of a new CAR-T cell therapy for adults with acute myeloid leukemia that has returned or not responded to other treatments. Doctors will collect a patient's own immune cells, modify them in a lab to target a protein on the cancer cells, and then infuse them back. The main goal is to see how safe the treatment is and if it can help put the cancer into remission.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Second Affiliated Hospital,School of Medicine,Zhejiang University
RECRUITINGHangzhou, Zhejiang, 310009, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.